文献速递角膜与眼表疾病

多重耐药MRSA角膜炎的临床结局与基因组流行病学

Clinical Outcomes and Genomic Epidemiology of Multidrug-Resistant Methicillin-Resistant Staphylococcus aureus Keratitis.
PubMed 文献 · Am J Ophthalmol · 2026-06-11

多数分离株(85.7%)为多重耐药,氟喹诺酮敏感性低(莫西沙星19.7%),全部对万古霉素敏感且未见中间型、异质性耐药或耐受表型;随访患者中85.2%最终视力差于20/60。全基因组测序以CC5(68.3%)和CC8(29.2%)为主,提示高耐药谱系在社区相关角膜感染中持续存在。

要点

  • 多数MRSA角膜炎分离株为多重耐药(85.7%),莫西沙星敏感性仅19.7%。
  • 全部分离株对万古霉素敏感(MIC₉₀ 2 µg/mL),未检出异质性耐药或耐受表型。
  • 尽管按指南治疗,随访患者中85.2%最终视力差于20/60。

核心结论

  • MRSA角膜炎多重耐药率高且视力结局差,感染主要由CC5多重耐药株引起,尽管近期医疗暴露有限。

研究设计与样本

  • 收集人口学与临床资料,行抗菌药物敏感性试验,多重耐药定义为对≥3类抗生素耐药。
  • 部分分离株行全基因组测序及核心基因组多位点序列分型,并对可用分离株行万古霉素敏感性、异质性耐药筛查和耐受试验。

主要发现

  • 中位年龄63.5岁,女性占61.4%;眼表疾病(67.7%)和既往眼手术(65.2%)常见,仅25.4%在前一年有显著医疗暴露。
  • 85.7%的分离株为多重耐药,莫西沙星敏感性为19.7%。
  • 全部分离株对万古霉素敏感(MIC₉₀ 2 µg/mL),未发现万古霉素中间型、异质性耐药或耐受表型。
  • 全基因组测序(n=41)显示克隆复合群5占68.3%、克隆复合群8占29.2%。
  • 有随访的患者中85.2%最终最佳矫正视力差于20/60。

关键数值与推荐

  • 多重耐药定义为对≥3类抗生素耐药。
  • 莫西沙星敏感性19.7%,万古霉素MIC₉₀为2 µg/mL。
  • 克隆复合群5占68.3%,克隆复合群8占29.2%(测序n=41)。
  • 随访患者中最终视力差于20/60者占85.2%。

临床怎么用

  • 对MRSA角膜炎应重视抗菌药物敏感性监测,因多重耐药率高且氟喹诺酮敏感性低。
  • 万古霉素体外活性良好,但即使按指南治疗视力结局仍较差,需优化治疗策略并加强随访。

局限性

  • 为两中心回顾性病例系列,样本量有限,部分分析仅基于可用分离株或测序子集,原文未报告其他局限说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize the clinical features, management, antimicrobial resistance patterns, and genomic epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) keratitis at two North American centers. DESIGN: Retrospective interventional case series combined with laboratory investigation PARTICIPANTS: Seventy eyes of 67 patients presenting laboratory-confirmed MRSA keratitis were included METHODS: We performed a multicenter retrospective case series of patients with culture-proven MRSA keratitis treated between 2005 and 2022. Demographic and clinical data were collected. Antimicrobial susceptibility testing was conducted, and multidrug resistance (MDR) was defined as resistance to ≥3 antibiotic classes. A subset of isolates underwent whole-genome sequencing with core genome multilocus sequence typing. Vancomycin susceptibility, heteroresistance screening, and tolerance testing were performed on available isolates. MAIN OUTCOME MEASURES: Antimicrobial susceptibility and multidrug resistance rates, vancomycin phenotypic profiles, MRSA genotypic distribution, and final best-corrected visual acuity RESULTS: Median age was 63.5 years, and 61.4% were female. Ocular surface disease (67.7%) and prior ocular surgery (65.2%) were common. Only 25.4% had significant healthcare exposure in the preceding year. Most isolates (85.7%) were MDR. Fluoroquinolone susceptibility was low (moxifloxacin 19.7%). All isolates were susceptible to vancomycin (MIC₉₀ 2 µg/mL), and no vancomycin-intermediate, heteroresistant, or tolerant phenotypes were identified. Whole genome sequencing (n = 41) demonstrated predominance of clonal complexes 5 (68.3%) and 8 (29.2%). Visual outcomes were poor, with most patients (85.2%) having a final visual acuity worse than 20/60 among those with follow-up. CONCLUSIONS: MRSA keratitis is associated with high rates of multidrug resistance and poor visual outcomes despite guideline-based therapy. Infections were predominantly caused by CC5 MDR strains despite limited recent healthcare exposure. These findings highlight the persistence of highly resistant MRSA lineages in community-associated corneal infection and underscore the need for ongoing antimicrobial surveillance and optimized treatment strategies.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cummings OW, Andre C, Ling J, et al. Clinical Outcomes and Genomic Epidemiology of Multidrug-Resistant Methicillin-Resistant Staphylococcus aureus Keratitis. Am J Ophthalmol. 2026. PMID: 42276184. doi:10.1016/j.ajo.2026.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。